Hemogenyx Pharmaceuticals plc (LON:HEMO), a pre-clinical stage biopharmaceutical company, announced on Friday that it has received clearance from the US Federal Food and Drug Administration (FDA) for Phase I trials of HEMO-CAR-T for the treatment of acute myeloid leukaemia (AML).
The FDA lifted the clinical hold on the Investigational New Drug (IND) application after the company addressed all identified issues satisfactorily.
Welcoming the decision, Dr Vladislav Sandler, CEO and co-founder of Hemogenyx Pharmaceuticals, said: "We now look forward to accelerating clinical development of HEMO-CAR-T and to offering patients a potentially life-saving treatment."
AML, the most common type of acute leukaemia in adults, is currently treated with chemotherapy and has poor survival rates. CAR-T therapy modifies a patient's T-cells to recognise and eliminate cancer cells, offering a potentially more benign and effective treatment for AML. The process involves isolating, modifying, amplifying and reintroducing the patient's T-cells.
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation